• 1
    Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 629.
  • 2
    Heney NM, Ahmed S, Flanagan MJ, et al: Superficial bladder cancer: Progression and recurrence. J Urol 1983; 130: 10831086.
  • 3
    Kaye KW, Lange PH: Mode of presentation of invasive bladder cancer: Reassessment of the problem. J Urol 1982; 128: 3133.
  • 4
    Prout GR Jr, Griffin PP, Shipley WU: Bladder carcinoma as a systemic disease. Cancer 1979; 43: 25322539.
  • 5
    Rehn L: Blasengeschwulte bei FuchsinArbeitern. Arch Klin Chir 1895; 50: 588.
  • 6
    Hueper WC, Wiley FH, Wolfe HD: Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. Hyg Tox 1938; 20: 46.
  • 7
    Case RAM, Hosker ME, McDonald DB, et al: Tumours of the urinary bladder in workmen engaged in the British chemical industry. Role of aryl benzidine, alpha-naphthylamine, and betanaphthylamine. Br J Intern Med 1954; 11: 75.
  • 8
    Morrison AS, Buring JE, Verhoeck WG, et al: An international study of smoking and bladder cancer. J Urol 1984; 131: 650654.
  • 9
    Clavel J, Cordier S, Boccon-Gibod L, et al: Tobacco and bladder cancer in males: Increased risk for inhalers and smokers of black tobacco. Int J Cancer 1989; 44: 605610.
  • 10
    Vineis P, Esteve J, Hartge P, et al: Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res 1998; 48: 38493852.
  • 11
    Ellwein LB, Cohen SM: The health risks of saccharin revisited. Crit Rev Toxicol 1990; 20: 311326.
  • 12
    Cartwright RA, Glashan RW, Rogers HJ, et al: The role of N-acetyltransferase in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2: 842845.
  • 13
    Mommsen S, Barfod NM, Aagaard J: N-acetyl-transferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 1985; 6: 199201.
  • 14
    Bartsch H, Caporaso N, Coda M, et al: Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers. J Natl Cancer Inst 1990; 82: 18261831.
  • 15
    Varkarakis MJ, Gaeta J, Moore RH, et al: Superficial bladder tumor: Aspects of clinical progression. Urology 1974; 4: 414420.
  • 16
    Badalament RA, Fair WR, Whitmore WF Jr, et al: The relative value of cytometry and cytology in the management of bladder cancer: The Memorial Sloan-Kettering Cancer Center experience. Semin Urol 1988; 6: 2230.
  • 17
    Sarosdy MF, deVere White RW, Soloway MS, et al: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379383.
  • 18
    Sarosdy MF, Hudson MA, Ellis WJ, et al: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997; 50: 349353.
  • 19
    Droller MJ: Commentary on Sarosdy MF et al: Improved detection of recurrent bladder cancer using the Bard BTA test. J Urol 1998; 159: 601.
  • 20
    Soloway MS, Briggman V, Carpinito GA, et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363367.
  • 21
    Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394.
  • 22
    Lin Y, Miyamoto H, Fujinami K, et al: Telomerase activity in human bladder cancer. Clin Cancer Res 1996; 2: 929932.
  • 23
    Kavaler E, Landman J, Chang Y, et al: Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998; 82: 708714.
  • 24
    Schmetter BS, Habicht KK, Lamm DL, et al: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801805.
  • 25
    Lokeshwar V, Phan H, Obeck C, et al: HA-HAase urine test for detecting bladder cancer and evaluating its grade. J Urol 1997; 157 (Suppl): 341.
  • 26
    Huland E, Huland H, Meier T, et al: Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol 1991; 146: 16311636.
  • 27
    Hall RR, Beynon LL, Horwich A, et al: Urology and the TNM classification. Lancet 1988; 1: 11451146.
  • 28
    Hermanek P, Sobin LH: UICC-International Union Against Cancer TNM Classification of Malignant Tumors. Heidelberg, Germany, Springer Verlag, 1987, p 133.
  • 29
    Droller MJ: Bladder cancer. Curr Probl Surg 1981; 18: 205279.
  • 30
    Jones PA, Droller MJ: Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol 1993; 11: 177192.
  • 31
    Fitzpatrick JM: Superficial Bladder Cancer: Natural History, Evaluation, and Management. Houston, American Urological Association, Inc., 1989. AUA Update Series.
  • 32
    Jakse G, Loidl W, Seeber G, et al: Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor? J Urol 1987; 137: 3943.
  • 33
    Abel PD: Follow-up of patients with ‘superficial’ transitional cell carcinoma of the bladder: The case for a change in policy. Br J Urol 1993; 72: 135142.
  • 34
    Prout GR Jr, Barton BA, Griffin PP, et al: Treated history of noninvasive grade 1 transitional cell carcinoma: The National Bladder Cancer Group. J Urol 1992; 148: 14131419.
  • 35
    Birch BR, Harland SJ: The pT1 G3 bladder tumour. Br J Urol 1986; 64: 109116.
  • 36
    Bostwick DG: Natural history of early bladder cancer. J Cell Biochem Suppl 1992; 161: 3138.
  • 37
    Kakizoe T, Tobisu K, Takai K, et al: Relationship between papillary and nodular transitional cell carcinoma in the human urinary bladder. Cancer Res 1988; 48: 22992303.
  • 38
    Pomerance A: Pathology and prognosis following total cystectomy for carcinoma of the bladder. Br J Urol 1972; 44: 451458.
  • 39
    Kakizoe T, Matumoto K, Nishio Y, et al: Significance of carcinoma in situ and dysplasia in association with bladder cancer. J Urol 1985; 133: 395398.
  • 40
    Aprikian AG, Sarkis AS, Reuter VE, et al: Biological markers of prognosis in transitional cell carcinoma of the bladder: Current concepts. Semin Urol 1993; 11: 137144.
  • 41
    Hopman AH, Moesker O, Smeets AW, et al: Numerical chromosome 1, 7, 9, and 11 alterations in bladder cancer detected by in situ hybridization. Cancer Res 1991; 51: 646651.
  • 42
    Tsai YC, Nichols PW, Hiti AL, et al: Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50: 4447.
  • 43
    Sidransky D, Messing E: Molecular genetics and biochemical mechanisms in bladder cancer: Oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am 1992; 19: 629639.
  • 44
    Raghavan D, Shipley WU, Garnick MB, et al: Biology and management of bladder cancer. N Engl J Med 1990; 322: 11291138.
  • 45
    Soto EA, Friedell GH, Tiltman AJ: Bladder cancer as seen in giant histologic sections. Cancer 1977; 39: 447455.
  • 46
    Prout GR Jr, Griffin PP, Shipley WU: Bladder carcinoma as a systemic disease. Cancer 1979; 43: 25322539.
  • 47
    Melicow MM: Histological study of vesical urothelium intervening between gross neoplasm in total cystectomy. J Urol 1952; 68: 261.
  • 48
    Hudson MA, Herr HW: Carcinoma in situ of the bladder. J Urol 1995; 153: 564572.
  • 49
    Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573580.
  • 50
    Lamm DL, van der Meijden AP, Akaza H, et al: Intravesical chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995; 2 (Suppl 2): 2335.
  • 51
    Althausen AF, Prout GR Jr, Daly JJ: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 575580.
  • 52
    Klän R, Loy V, Huland H: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991; 146: 316318.
  • 53
    Brosman SA, Lamm DL: The preparation, handling and use of intravesical bacillus Calmette-Guérin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer. J Urol 1990; 144: 313315.
  • 54
    Lamm DL: Carcinoma in situ. Urol Clin North Am 1992; 19: 499508.
  • 55
    Lamm DL, Steg A, Boccon-Gibod L, et al: Complications of bacillus Calmette-Guérin immunotherapy: Review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989; 310: 335355.
  • 56
    Merz VW, Marth D, Kraft R, et al: Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. Br J Urol 1995; 75: 180184.
  • 57
    Herr HW, Schwalb DM, Zhang ZF, et al: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13: 14041408.
  • 58
    Sell A, Jakobsen A, Nerstrom B, et al: Treatment of advanced bladder cancer category T2, T3, and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor: DAVECA Protocol 8201: Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991; 138: 193201.
  • 59
    Skinner DG, Lieskovsky G: Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984; 131: 10691072.
  • 60
    Messing EM, Young TB, Hunt VB, et al: The significance of asymptomatic microhematuria in men 50 or more years old: Findings of a home screening study using urinary dipsticks. J Urol 1987; 137: 919922.
  • 61
    Howard RS, Golin AL: Long-term follow-up of asymptomatic microhematuria. J Urol 1991; 145: 335336.
  • 62
    Sternberg CN, Yagoda A, Scher HI, et al: MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461469.
  • 63
    Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group study. J Clin Oncol 1985; 3: 14631470.
  • 64
    Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 10501055.
  • 65
    Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al: Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995; 153: 964973.
  • 66
    Hall RR: Bladder preserving treatment: The role of transurethral surgery alone and with combined modality therapy for muscle-invading bladder cancer, in VogelzangNJ, ScardinoPT, ShipleyWU (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, Williams & Wilkins, 1995, p 509.
  • 67
    Prout GR Jr, Shipley WU, Kaufman DS, et al: Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer: A bladder-sparing trial. Urol Clin North Am 1991; 18: 547554.
  • 68
    Wajsman Z, Marino R, Parsons J, et al: Bladder-sparing approach in the treatment of invasive bladder cancer. Semin Urol 1990; 8: 210215.
  • 69
    Herr HW: Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 1987; 138: 11621163.
  • 70
    Solsona E, Iborra I, Ricos, JV, et al: Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: Prospective study. J Urol 1992; 147: 15131515.
  • 71
    Slack NH, Prout GR Jr: Heterogeneity of invasive bladder carcinoma and different responses to treatment, in BonneyWW, ProutGR (eds): Bladder Cancer. Baltimore, Williams & Wilkins, 1980, p 213. AUA Monographs, vol. 1.
  • 72
    Jewett HJ, Strong GH: Infiltrating carcinoma of the bladder: Relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J Urol 1946; 55: 366.
  • 73
    Koss LG: Tumors of the Urinary Bladder. Washington, DC, Armed Forces Institute of Pathology, 1974. Atlas of Tumor Pathology, Second Series, Fascicle 11.